| Literature DB >> 33917778 |
Ciara Cooney1, Ed Daly1, Maria McDonagh1, Lisa Ryan1.
Abstract
The primary objective of this study was to compare weight changes in two groups of ageing Irish adults with overweight and adiposity-based chronic disease: participants who had dietary energy requirements prescribed on the base of measured RMR and participants whose RMR was estimated by a prediction equation. Fifty-four Caucasian adults (male n = 25; female n = 29, age 57.5 ± 6.3 years, weight 90.3 ± 15.1 kg, height 171.5 ± 9.5 cm, BMI 30.7 ± 4.6 kg/m2) were randomly assigned to a dietary intervention with energy prescription based on either measured RMR or estimated RMR. RMR was measured by indirect calorimetry after an overnight fast and predicted values were determined by the Mifflin et al. (1990) prediction equation. All participants received individual nutritional counselling, motivational interviewing and educational material. Anthropometric variables, blood pressure, blood glucose and blood lipid profile were assessed over 12 weeks. Body weight at week 12 was significantly lower (p < 0.05) for both groups following dietary interventions, mRMR: -4.2%; eRMR: -3.2% of initial body weight. There was no significant difference in weight loss between groups. Overall, 20.8% mRMR and 17.4% of eRMR participants experienced clinically meaningful (i.e., ≥5% of initial weight) weight reduction. Weight reduction in adults aged ≥50 years over the short term (12 weeks) favoured a reduction in blood pressure, triglycerides and glucose, thus reducing cardiovascular disease risk factors. This research indicates that employing a reduced-calorie diet using indirect calorimetry to determine energy needs when improving weight outcomes in adults (>50 years) with overweight and adiposity-based chronic disease is equal to employing a reduced-calorie diet based on the Mifflin et al. (1990) prediction equation. A reduced-energy diet based on mRMR or eRMR facilitates clinically meaningful weight reduction in adults (≥50 years) over the short term (12 weeks) and favours a reduction in blood pressure, triglycerides and glucose, thus reducing cardiovascular disease risk factors. Moreover, the addition of motivational interviewing and behaviour change techniques that support and encourage small behaviour changes is effective in short-term weight management.Entities:
Keywords: adiposity-based chronic disease; ageing adults; energy balance; metabolism; obesity; overweight; prediction equation; resting metabolic rate
Mesh:
Substances:
Year: 2021 PMID: 33917778 PMCID: PMC8068182 DOI: 10.3390/nu13041229
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Baseline participant characteristics.
|
| mRMR Group |
| eRMR Group | ||
|---|---|---|---|---|---|
| Sex males (M) females (F) | M10/F19 | M15/F10 | |||
| Age (years) | 29 | 56.7 ± 5.3 | 25 | 58.6 ± 7.1 | |
| Height (cm) | 29 | 170.3 ± 9.5 | 25 | 173.1 ± 8.8 | |
| Weight (kg) | 29 | 88.5 (81.0, 94.8) | 25 | 92.9 (81.0, 98.9) | † |
| BMI (kg/m2) | 29 | 29.3 (26.8, 33.4) | 25 | 29.5 (27.7, 32.6) | † |
| WC (cm) | 28 | 106.0 (99.3, 115.3) | 25 | 112.5 (102.5, 116.0) | † |
| HC (cm) | 28 | 112.3 (106.0, 126.1) | 25 | 113.0 (107.3, 123.0) | † |
| WHR | 28 | 0.9 ± 0.1 | 25 | 1.0 ± 0.1 | ᶲ |
| Body Fat (%) | 29 | 37.5 ± 8.6 | 25 | 35.7 ± 7.5 | † |
| Muscle Mass (kg) | 29 | 49.1 (45.1, 63.0) | 25 | 59.6 (44.6, 67.3) | ᶲ |
| BPsys (mmHg) | 29 | 126.0 (115.5, 136.0) | 25 | 135.0 (124.0, 151.0) | † |
| BPdia (mmHg) | 29 | 83.0 (74.5, 87.5) | 25 | 87.0 (78.0, 92.0) | † |
| Glucose (mmol/L) | 28 | 4.9 (4.5, 5.5) | 25 | 5.3 (4.5, 5.8) | † |
| TC (mmol/L) | 28 | 4.7 (4.1, 5.3) | 22 | 3.9 (3.5, 4.5) | † |
| HDL (mmol/L) | 28 | 1.3 (1.1, 1.8) | 23 | 1.2 (1.1, 1.6) | † |
| TC:HDL Ratio | 28 | 3.4 (2.6, 4.1) | 21 | 3.0 (2.4, 3.4) | † |
| LDL (mmol/L) | 24 | 2.8 (2.5, 3.1) | 19 | 2.2 (1.7, 2.6) | † |
| TG (mmol/L) | 25 | 1.1 (0.9, 1.4) | 19 | 1.2 (1.0, 1.6) | † |
| mRMR (kcal) | 29 | 1604.0 (1374.0, 2011.5) | 23 | 1691.0 (1455.0, 2067.0) | † |
| RER | 29 | 0.8 (0.7, 0.9) | 23 | 0.8 (0.7, 0.9) | † |
| eRMR kcal | 29 | 1560.3 ± 221.7 | 24 | 1639.3 ± 272.2 | ᶲ |
| Energy Intake (kcal) | 21 | 2195.0 (1863.5, 2755.0) | 19 | 2129.0 (1880.0, 2586.0) | † |
Values are presented as the mean ± SD or median (25th–75th percentile), if data were non-parametric. n = number of participants with data available for each outcome. IQR, interquartile range; BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist to hip ratio; BPsys, systolic blood pressure; BPdia, diastolic blood pressure; TC, total cholesterol; HDL, high-density lipoprotein; TC:HDL, total cholesterol to high-density lipoprotein ratio; LDL, low-density lipoprotein; TG, triglycerides; RMR, resting metabolic rate; RER, respiratory exchange ratio; ᶲ denotes independent-samples t-test; † denotes Mann–Whitney U test.
Anthropometric and clinical outcomes across the intervention period.
| mRMR Group | eRMR Group | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Baseline | Week 3 | Week 6 | Week 12 |
| Baseline | Week 3 | Week 6 | Week 12 | Time Effect, | Group Effect, | Time-by-Group Interaction, | |
| Weight (kg) | 22 | 89.0 ± 13.6 | 87.3 ± 13.7 | 86.7 ± 13.6 | 86.0 ± 13.7 | 17 | 93.7 ± 18.7 | 92.0 ± 17.8 | 90.5 ± 17.0 | 90.7 ± 17.8 | |||
| BMI (kg/m2) | 24 | 30.4 ± 5.2 | 29.4 ± 5.2 | 23 | 31.1 ± 4.4 | 30.4 ± 4.0 | |||||||
| WC (cm) | 23 | 109.0 ± 13.9 | 98.2 ± 11.8 | 23 | 113.2 ± 12.3 | 105.5 ± 11.1 | |||||||
| HC (cm) | 23 | 117.2 ± 14.5 | 108.6 ± 10.4 | 23 | 117.0 ± 13.7 | 108.8 ± 8.1 | |||||||
| WHR | 23 | 0.9 ± 0.1 | 0.9 ± 0.1 | 23 | 1.0 ± 0.1 | 1.0 ± 0.1 | |||||||
| Body Fat (%) | 22 | 36.5 ± 9.2 | 36.7 ± 9.6 | 35.3 ± 9.5 | 36.9 ± 11.3 | 17 | 36.3 ± 7.0 | 35.3 ± 7.7 | 35.0 ± 7.2 | 35.6 ± 7.7 | |||
| Muscle Mass (kg) | 22 | 54.0 ± 11.7 | 52.7 ± 11.8 | 53.4 ± 11.4 | 51.8 ± 12.8 | 17 | 57.2 ± 13.3 | 56.9 ± 12.9 | 56.5 ± 13.3 | 56.0 ± 13.2 | |||
| BPsys (mmHg) | 23 | 124.0 ± 15.4 | 121.2 ± 14.3 | 23 | 137.8 ± 20.5 | 130.8 ± 16.2 | |||||||
| BPdia (mmHg) | 23 | 81.2 ± 11.7 | 77.9 ± 9.0 | 23 | 86.7 ± 9.8 | 83.8 ± 9.7 | |||||||
Values are presented as the mean ± SD. n = number of participants with complete data available for each outcome. p value obtained from a two-way mixed ANOVA test. * denotes significant difference, p < 0.05. BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist to hip ratio; BPsys, systolic blood pressure; BPdia, diastolic blood pressure.
Primary outcome weight pre and post intervention.
| mRMR Group | eRMR Group | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| Baseline | Week 12 |
| Baseline | Week 12 | Time Effect, | Group Effect, | Time-by-Group Interaction, | |
| Weight (kg) | 24 | 88.0 ± 13.7 | 85.2 ± 13.6 | 23 | 93.5 ± 17.4 | 91.4 ± 16.8 | |||
Values are presented as the mean ± SD. n = number of participants. p value obtained from a two-way mixed ANOVA test on pre and post data only. *denotes significant difference from baseline, p < 0.05.
Figure 1Weight (kg) across the intervention period for the mRMR (n = 22) and eRMR (n = 17) groups.
Figure 2Individual response to weight change for participants completing pre and post measures in the mRMR (n = 24) and eRMR groups (n = 23).
Biochemical outcomes at baseline and week 12.
| mRMR Group | eRMR Group | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| Baseline | Week 12 |
| Baseline | Week 12 | Time Effect, | Group Effect, | Time-by-Group Interaction, | |
| Glucose (mmol/L) | 23 | 5.0 ± 0.7 | 4.7 ± 0.7 | 22 | 5.4 ± 0.9 | 5.1 ± 0.8 | |||
| TC (mmol/L) | 23 | 4.5 ± 1.1 | 4.4 ± 1.0 | 20 | 4.1 ± 0.7 | 4.2 ± 0.9 | |||
| HDL (mmol/L) | 23 | 1.4 ± 0.4 | 1.3 ± 0.4 | 21 | 1.4 ± 0.4 | 1.3 ± 0.3 | |||
| TC:HDL Ratio | 23 | 3.4 ± 0.9 | 3.6 ± 0.9 | 19 | 3.0 ± 0.6 | 3.2 ± 0.8 | |||
| LDL (mmol/L) | 19 | 2.7 ± 0.7 | 2.6 ± 0.8 | 17 | 2.0 ± 0.6 | 2.3 ± 0.8 | |||
| TG (mmol/L) | 20 | 1.2 ± 0.5 | 1.1 ± 0.4 | 18 | 1.3 ± 0.4 | 1.2 ± 0.4 | |||
Values are presented as the mean ± SD. n = number of participants with complete data available for each outcome. p value obtained from a two-way mixed ANOVA test. TC, total cholesterol; HDL, high-density lipoprotein; TC:HDL, total cholesterol to high-density lipoprotein ratio; LDL, low-density lipoprotein; TG, triglycerides. *denotes significant difference, p < 0.05.
Figure 3Blood glucose (mmol/L) measured at baseline and week 12 for the mRMR (n = 23) and eRMR groups (n = 22).
Figure 4Total cholesterol (mmol/L) measured at baseline and week 12 for the mRMR (n = 23) and eRMR groups (n = 20).
Figure 5High-density lipoprotein (mmol/L) measured at baseline and week 12 for the mRMR (n = 23) and eRMR groups (n = 20).
Figure 6Total cholesterol to high-density lipoprotein ratio calculated at baseline and week 12 in both the mRMR (n = 23) and estimated eRMR groups (n = 19) groups.
Figure 7Low-density lipoprotein (mmol/L) calculated at baseline and week 12 for the mRMR (n = 19) and eRMR groups (n = 17).
Figure 8Triglycerides (mmol/L) measured at baseline and week 12 for the mRMR (n = 20) and eRMR groups (n = 18).
Metabolic outcomes and estimated energy intake for groups across the intervention period.
| Variable | mRMR Group | eRMR Group | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Baseline | Week 3 | Week 6 | Week 12 |
| Baseline | Week 3 | Week 6 | Week 12 | Time Effect, | Group Effect, | Time-by-Group Interaction, | |
| mRMR (kcal) | 22 | 1764.3 ± 547.6 | 1687.7 ± 505.8 | 1737.8 ± 475.1 | 1688.3 ± 454.6 | 16 | 1813.8 ± 410.4 | 1688.8 ± 469.6 | 1787.4 ± 566.5 | 1780.5 ± 518.8 | |||
| RER | 22 | 0.8 ± 0.2 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 | 16 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 | |||
| eRMR (kcal) | 22 | 1578.5 ± 227.7 | 1576.0 ± 230.9 | 1553.7 ± 222.5 | 1547.0 ± 225.0 | 17 | 1656.9 ± 297.7 | 1648.4 ± 276.4 | 1624.1 ± 282.2 | 1625.5 ± 288.0 | |||
| eEI (kcal) | 15 | 2327.3 ± 827.1 | 1841.1 ± 534.3 | 15 | 2117.3 ± 562.8 | 1645.1 ± 433.3 | |||||||
Values are presented as the mean ± SD. n = number of participants with complete data set available for each variable. p value obtained from a two-way mixed ANOVA test. * denotes significant difference, p < 0.05. mRMR, measured resting metabolic rate; RER, respiratory exchange ratio; eRMR, estimated resting metabolic rate (Mifflin-St. Jeor equation); eEI, estimated energy intake (group analysis from a 3-day food diary).
Estimated energy intake at baseline and week 12 for male and female participants.
| Intervention Group | Sex |
| Baseline | Week 12 | Sex |
| Baseline | Week 12 | |
|---|---|---|---|---|---|---|---|---|---|
| eEI (kcal) | mRMR | M | 5 | 2462 ± 973 | 2052 ± 597 | F | 10 | 2260 ± 793 | 1736 ± 473 |
| eRMR | M | 8 | 2267 ± 724 | 1804 ± 445 | F | 15 | 1947 ± 253 | 1463 ± 367 |
Values are presented as the mean ± SD. n = number of participants with complete data available at each time point. eEI, estimated energy intake (from a a3 day food diary) for male and female participants.
Prescribed energy intake versus estimated energy intake at week 12 for male and female participants.
| Intervention Group | Sex |
| Prescribed | Estimated | Sex |
| Prescribed | Estimated | |
|---|---|---|---|---|---|---|---|---|---|
| Energy Intake (kcal) | mRMR | M | 5 | 2180 ± 253 | 2052 ± 597 | F | 10 | 1584 ± 271 | 1736 ± 473 |
| eRMR | M | 8 | 2100 ± 236 | 1804 ± 445 | F | 15 | 1500 ± 141 | 1463 ± 367 |
Values are presented as the mean ± standard deviation. n = number of participants with complete data set available at each time point. Estimated 12-week daily average energy intake from a 3-day food diaries.